Retrospective data for AYAs treated on representative pediatric or adult ALL protocols
| Trial . | Pediatric . | Adult . |
|---|---|---|
| FRALLE-93/LALA-9428 | 5-y EFS: 67% | 5-y EFS: 41% |
| CALGB/CCG34 | 7-y EFS: 63% | 7-y EFS: 34% |
| MRC ALL 97-99/UKALLXII-E299329 | 5-y EFS: 65% | 5-y EFS: 49% |
| GIMEMA/AIEOP30 | 2-y OS: 80% | 2-y OS: 71% |
| HOVON/DCOG31 | 5-y EFS: 71% | 5-y EFS: 38% |
| Adult ALL Grp/NOPHO-9232 | 5-y OS: 74% | 5-y OS: 39% |
| Finnish Leukemia/NOPHO33 | 5-y OS: 67% | 5-y OS: 60% |
| Trial . | Pediatric . | Adult . |
|---|---|---|
| FRALLE-93/LALA-9428 | 5-y EFS: 67% | 5-y EFS: 41% |
| CALGB/CCG34 | 7-y EFS: 63% | 7-y EFS: 34% |
| MRC ALL 97-99/UKALLXII-E299329 | 5-y EFS: 65% | 5-y EFS: 49% |
| GIMEMA/AIEOP30 | 2-y OS: 80% | 2-y OS: 71% |
| HOVON/DCOG31 | 5-y EFS: 71% | 5-y EFS: 38% |
| Adult ALL Grp/NOPHO-9232 | 5-y OS: 74% | 5-y OS: 39% |
| Finnish Leukemia/NOPHO33 | 5-y OS: 67% | 5-y OS: 60% |
EFS indicates event-free survival; and OS, overall survival.